Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Thoracic Cancer|March 12, 2021
Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistanceMasaya Nishino, Kenichi Suda, Takamasa Koga, et al.Lung Cancer (Amsterdam, Netherlands)|February 25, 2021
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancerShuta Ohara, Kenichi Suda, Toshio Fujino, et al.Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitroMasaya Nishino, Kenichi Suda, Yoshihisa Kobayashi, et al.Cancers|December 30, 2025
Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung CancerMasaya Nishino, Hideki Ujiie, Masaoki Ito, et al.Clinical Lung Cancer|October 27, 2021
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic CarcinomasToshio Fujino, Kenichi Suda, Kazuko Sakai, et al.Lung Cancer (Amsterdam, Netherlands)|August 30, 2020
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Keiko Obata, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2019
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In VitroToshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 8, 2018
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to DacomitinibYoshihisa Kobayashi, Toshio Fujino, Masaya Nishino, et al.Clinical Lung Cancer|April 4, 2026
Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR MutationKenichi Suda, Kazuko Sakai, Masaoki Ito, et al.Translational Lung Cancer Research|September 29, 2021
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro studyTakamasa Koga, Kenichi Suda, Masaya Nishino, et al.Pageof 5